RxDoctor Payments Data

Li Sun, MD

Internal Medicine · Round Rock, TXNPI 1730446014

Payments from drug & device makers

$586in general payments, 2019–2025

Across 18 payments — averaging $32.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$123
  • Alphatec Spine, Inc$120
  • GSK$108
  • GE HealthCare$101
  • Merck$47
  • Johnson & Johnson$45
  • plus $42 from 2 others

What the payments were for

  • Travel & lodging$6511%
  • Food & beverage$52289%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Globus Medical9$123
Alphatec Spine, Inc1$120
GSK1$108
GE HealthCare1$101
Merck2$47
Johnson & Johnson1$45
Pfizer2$29
AbbVie1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$586 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$95,473
Medicare patients
314
Services billed
1,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$61,898
MounjaroTirzepatide51$56,834
JardianceEmpagliflozin29$38,589
EliquisApixaban26$29,698
LinzessLinaclotide22$19,327
Tresiba Flextouch U-100Insulin Degludec15$18,006
XareltoRivaroxaban12$6,845
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$6,794
Atorvastatin Calcium403$4,695
Losartan Potassium308$4,122
Levothyroxine Sodium294$3,655
Lidocaine19$3,217
SynthroidLevothyroxine Sodium37$3,024
Rosuvastatin Calcium160$2,386
Albuterol Sulfate HfaAlbuterol Sulfate59$2,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$29,69826 claims
AbbVieLinzess, Synthroid$14$22,35159 claims
Johnson & JohnsonXarelto$45$6,84512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →